

Frontotemporal dementia - Pipeline Insight, 2021

<https://marketpublishers.com/r/FF3714F82886EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: FF3714F82886EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Frontotemporal dementia - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Frontotemporal dementia Understanding

Frontotemporal dementia: Overview

Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer's disease in the 45–64 age group.

'Frontotemporal dementia - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal dementia.

Frontotemporal dementia Emerging Drugs Chapters

This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Frontotemporal dementia Emerging Drugs

PR006: Prevail Therapeutics

PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). Like PR001, PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9. The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The

European Commission has granted orphan designation for PR006 for the treatment of FTD. PR006 is currently being studied in our PROCLAIM trial, a Phase I/II clinical trial of PR006 for the treatment of patients with FTD-GRN.

AL001: Alector

AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the bloodstream to increase the levels of PGRN in the brains of FTD-GRN patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018. Currently, it is in phase III stage of development to treat Frontotemporal dementia.

Further product details are provided in the report.....

Frontotemporal dementia: Therapeutic Assessment

This segment of the report provides insights about the different Frontotemporal dementia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Frontotemporal dementia

There are approx. 20+ key companies which are developing the therapies for Frontotemporal dementia. The companies which have their Frontotemporal dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Frontotemporal dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Frontotemporal dementia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.

Frontotemporal dementia Report Insights

Frontotemporal dementia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Frontotemporal dementia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Frontotemporal dementia drugs?

How many Frontotemporal dementia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal dementia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal dementia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Frontotemporal dementia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Alector

Prevail Therapeutics

Passage Bio, Inc.

TauRx Pharmaceuticals

Wave Life Sciences Ltd.

CAMP4 Therapeutics

Coya Therapeutics

SOLA Biosciences

AcuraStem

Denali Therapeutics

Wave Life Sciences

Neurimmune

Biogen

Asceneuron SA

Libra Therapeutics

Muna Therapeutics

Alkermes

DEEP GENOMICS

Sangamo Therapeutics

LOCANABIO

Arkuda Therapeutics

AZTherapies

Yumanity

Autifony Therapeutics

Prothena

Key Products

PR006

AL 001

PBFT02

TRx-0237

WVE-004

EXO-050

SOL 257

AS 201

AS 202

DNL593

NI308

NI205

Contents

Introduction

Executive Summary

Frontotemporal dementia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

AL001: Alector

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

PR006: Prevail Therapeutics

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
 Comparative Analysis
EXO-050: Coya Therapeutics
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
 Comparative Analysis
Frontotemporal dementia Key Companies
Frontotemporal dementia Key Products
Frontotemporal dementia- Unmet Needs
Frontotemporal dementia- Market Drivers and Barriers
Frontotemporal dementia- Future Perspectives and Conclusion
Frontotemporal dementia Analyst Views
Frontotemporal dementia Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Frontotemporal dementia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Frontotemporal dementia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Frontotemporal dementia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/FF3714F82886EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FF3714F82886EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970